Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer

Experts discuss other therapies or clinical trials that might be explored after trastuzumab deruxtecan, particularly for patients with HER2-positive microsatellite-stable (MSS) adenocarcinoma and progression on multiple lines of therapy.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Robert’s Journey With HER2  Upper GI Cancer

EP: 2.Frontline Treatment and Molecular Testing in Upper GI Cancer: Precision-Guided Therapy

EP: 3.Reflex Testing in Upper GI Cancer: Optimizing Molecular Insights for Timely Treatment

EP: 4.The Role of Biomarkers for Immunotherapy Selection in Upper GI Cancer

EP: 5.Reassessing Biomarkers: Guiding Second-Line Therapy in Upper GI Cancer

EP: 6.Navigating Prognosis and Treatment Goals in Upper GI Cancer: A Patient- and Family-Centered Approach

EP: 7.Megan’s Journey With HER2+ Upper GI Cancer

EP: 8.Understanding PD-L1 CPS: Impact on Treatment Decisions in HER2+ Gastric Cancer

EP: 9.Trastuzumab Deruxtecan in HER2+ Gastric Cancer: Insights From DESTINY-Gastric02

EP: 10.Biomarkers and Clinical Features Guiding HER2-Directed Therapy in Upper GI Cancer

EP: 11.MSS Status and Pembrolizumab: Assessing Benefits and Considering Combinations Beyond Progression in Upper GI Cancer

Now Viewing

EP: 12.Exploring Next-Line Options: Therapies Beyond Trastuzumab Deruxtecan in HER2+ MSS Gastric Cancer

Video content above is prompted by the following:

• What other therapies or clinical trials might be explored after trastuzumab deruxtecan, particularly in patients with HER2+ MSS adenocarcinoma and progression on multiple lines of therapy?

Recent Videos

Frontline Setting of Pancreatic Cancer

Treatment Algorithm for Metastatic Pancreatic Cancer

Role of Radiation in Pancreatic Cancer Treatment

NGS and Germline Testing in Pancreatic Cancer

Overview of Pancreatic Cancer Treatment Approach

BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

The Future of DLBCL: Innovations in Therapy and Patient Care

Overview of BESPOKE Patient Characteristics

Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making

Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions